Physician profile
Ashley Schaefer
NPI 1942452511
$10,442.30
in general payments reported to CMS, 2019-2025
24 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,573 · 2022: $1,676 · 2023: $2,295 · 2024: $1,755 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,785 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,784.96 |
| Education | $408.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,377.32 | 2021-2025 | |
| Amgen INC. | $1,075.25 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $874.45 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $809.43 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $668.59 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $652.07 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Janssen Biotech, INC. | $626.57 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $380.05 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Astrazeneca Pharmaceuticals LP | $352.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $315.33 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $246.81 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $202.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $175.64 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $160.17 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $149.24 | 2022-2025 | Adbry, Anzupgo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $127.02 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $76.00 | 2022-2024 | |
| Dermavant Sciences, INC. | $48.07 | 2023-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $27.37 | 2025 | Valchlor |
| Organon LLC | $22.75 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.41 | 2023 | Spevigo |
| Dermira, INC. | $19.42 | 2021 | |
| Journey Medical Corporation | $18.29 | 2023 | |
| Merck Sharp & Dohme LLC | $17.04 | 2025 | Enflonsia, Rotateq, Vaxelis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.